Robbin Itzler
About
Robbin Itzler is a scholar working on Infectious Diseases, Hepatology and Cardiology and Cardiovascular Medicine.
According to data from OpenAlex, Robbin Itzler has authored 34 papers receiving a total of 2.5k indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Infectious Diseases, 12 papers in Hepatology and 11 papers in Cardiology and Cardiovascular Medicine. Recurrent topics in Robbin Itzler's work include Viral gastroenteritis research and epidemiology (16 papers), Hepatitis Viruses Studies and Epidemiology (12 papers) and Viral Infections and Immunology Research (10 papers). Robbin Itzler is often cited by papers focused on Viral gastroenteritis research and epidemiology (16 papers), Hepatitis Viruses Studies and Epidemiology (12 papers) and Viral Infections and Immunology Research (10 papers). Robbin Itzler collaborates with scholars based in United States, Finland and Netherlands. Robbin Itzler's co-authors include Neil Hawkins, Jeroen P. Jansen, Annabel Barrett, Joseph C. Cappelleri, Cornelis Boersma, James M. Pellissier, Ralph P. Insinga, Patricia Saddier, Rachael Fleurence and Lieven Annemans and has published in prestigious journals such as PEDIATRICS, American Journal of Public Health and Journal of General Internal Medicine.
In The Last Decade
Robbin Itzler
34 papers receiving 2.4k citations
Hit Papers
Peers
Robbin Itzler
Samir Haffar United States
I. Guggenmoos-Holzmann Germany
Arthur Weinstein United States
Fateh Bazerbachi United States
Lang Chen United States
Fenglong Xie United States
Andrew Hall United Kingdom
Victoria Nyawira Nyaga Belgium
Peter Braun Germany
Dorothee M. Aeppli United States
Citations per year, relative to Robbin Itzler Robbin Itzler (= 1×)
peers
Samir Haffar
Countries citing papers authored by Robbin Itzler
Since
Specialization
Citations
This map shows the geographic impact of Robbin Itzler's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robbin Itzler with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robbin Itzler more than expected).
Fields of papers citing papers by Robbin Itzler
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Robbin Itzler. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robbin Itzler. The network helps show where Robbin Itzler may publish in the future.
Co-authorship network of co-authors of Robbin Itzler
This figure shows the co-authorship network connecting the top 25 collaborators of Robbin Itzler. A scholar is included among the top collaborators of Robbin Itzler based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Robbin Itzler. Robbin Itzler is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Itzler, Robbin, Tyler W. Buckner, Frank W.G. Leebeek, et al.. (2024). Effect of etranacogene dezaparvovec on quality of life for severe and moderately severe haemophilia B participants: Results from the phase III HOPE‐B trial 2 years after gene therapy. Haemophilia. 30(3). 709–719.
2.
Itzler, Robbin, et al.. (2024). An international survey assessing the effects of the duration of attack-free period on health-related quality of life for patients with hereditary angioedema. Orphanet Journal of Rare Diseases. 19(1). 241–241.
3.
Farhadfar, Nosha, Helen Leather, Shu Wang, et al.. (2021). Severity of Acute Graft-Versus-Host Disease and Associated Healthcare Resource Utilization, Cost and Outcomes. Transplantation and Cellular Therapy. 27(3). S23–S23.
4.
Hart, Allyson, David P. Schladt, Arthur J. Matas, et al.. (2021). Incidence, risk factors, and long‐term outcomes associated with antibody‐mediated rejection — The long‐term Deterioration of Kidney Allograft Function (DeKAF) prospective cohort study. Clinical Transplantation. 35(7). e14337–e14337.
5.
Farhadfar, Nosha, Helen Leather, Shu Wang, et al.. (2021). Severity of Acute Graft-versus-Host Disease and Associated Healthcare Resource Utilization, Cost, and Outcomes. Transplantation and Cellular Therapy. 27(12). 1007.e1–1007.e8.
6.
Itzler, Robbin, et al.. (2014). Cost-Effectiveness of Posaconazole Versus Fluconazole or Itraconazole in the Prophylaxis of Invasive Fungal Infections Among Neutropenic Patients in Thailand. Value in Health. 17(7). A806–A806.
7.
Matson, David O., Timo Vesikari, Penelope H. Dennehy, et al.. (2014). Analysis by rotavirus gene 6 reverse transcriptase-polymerase chain reaction assay of rotavirus-positive gastroenteritis cases observed during the vaccination phase of the Rotavirus Efficacy and Safety Trial (REST). Human Vaccines & Immunotherapeutics. 10(8). 2267–2275.
8.
Matson, David O., Mary Allen Staat, Parvin H. Azimi, et al.. (2012). Burden of rotavirus hospitalisations in young children in three paediatric hospitals in the United States determined by active surveillance compared to standard indirect methods. Journal of Paediatrics and Child Health. 48(8). 698–704.
9.
Hoaglin, David C., Neil Hawkins, Jeroen P. Jansen, et al.. (2011). Conducting Indirect-Treatment-Comparison and Network-Meta-Analysis Studies: Report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: Part 2. Value in Health. 14(4). 429–437.
10.
Dennehy, Penelope H., Timo Vesikari, David O. Matson, et al.. (2011). Efficacy of the pentavalent rotavirus vaccine, RotaTeq® (RV5), between doses of a 3-dose series and with less than 3 doses (incomplete regimen). Human Vaccines. 7(5). 563–568.
11.
Jansen, Jeroen P., Rachael Fleurence, Beth Devine, et al.. (2011). Interpreting Indirect Treatment Comparisons and Network Meta-Analysis for Health-Care Decision Making: Report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: Part 1. Value in Health. 14(4). 417–428.
12.
Itzler, Robbin, Gary G. Koch, David O. Matson, et al.. (2010). Robustness of the healthcare utilization results from the Rotavirus Efficacy and Safety Trial (REST) evaluating the human-bovine (WC3) reassortant pentavalent rotavirus vaccine (RV5). BMC Pediatrics. 10(1). 42–42.
13.
Goveia, Michelle G., et al.. (2010). EFFICACY AND SAFETY OF PENTAVALENT HUMAN-BOVINE REASSORTANT ROTAVIRUS VACCINE WHEN ADMINISTERED WITH GREATER THAN 10 WEEKS BETWEEN DOSES. The Pediatric Infectious Disease Journal. 29(3). 263–265.
14.
Singhal, Puneet K., et al.. (2009). Incremental 1-Year Medical Resource Utilization and Costs for Patients with Herpes Zoster from a Set of US Health Plans. PharmacoEconomics. 27(9). 781–792.
15.
Bertozzi, Stefano, et al.. (2008). Cost-effectiveness of introducing a rotavirus vaccine in developing countries: The case of Mexico. BMC Infectious Diseases. 8(1). 103–103.
16.
Vesikari, Timo, Robbin Itzler, David O. Matson, et al.. (2008). ROTATEQ® REDUCED HOSPITALIZATIONS AND EMERGENCY DEPARTMENT VISITS FOR ROTAVIRUS ACUTE GASTROENTERITIS: ASSESSING THE ROBUSTNESS OF THE RESULTS. Archives of Disease in Childhood. 93.
17.
Vesikari, Timo, Robbin Itzler, David O. Matson, et al.. (2007). Efficacy of a pentavalent rotavirus vaccine in reducing rotavirus-associated health care utilization across three regions (11 countries). International Journal of Infectious Diseases. 11. S29–S35.
18.
Insinga, Ralph P., Robbin Itzler, & James M. Pellissier. (2007). Acute/Subacute Herpes Zoster. PharmacoEconomics. 25(2). 155–169.
19.
Insinga, Ralph P., Robbin Itzler, James M. Pellissier, Patricia Saddier, & Alexander Nikas. (2005). The incidence of herpes zoster in a United States administrative database. Journal of General Internal Medicine. 20(8). 748–753.
20.
Bakhai, Ameet, Marcus Flather, J Collinson, et al.. (2003). National economic impact of tirofiban for unstable angina and myocardial infarction without ST elevation; example from the United Kingdom. International Journal of Cardiology. 91(2-3). 163–172.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Samir Haffar Breakdown of academic impact, for papers by I. Guggenmoos-Holzmann Breakdown of academic impact, for papers by Arthur Weinstein Breakdown of academic impact, for papers by Fateh Bazerbachi Breakdown of academic impact, for papers by Lang Chen Breakdown of academic impact, for papers by Fenglong Xie Breakdown of academic impact, for papers by Andrew Hall Breakdown of academic impact, for papers by Victoria Nyawira Nyaga Breakdown of academic impact, for papers by Peter Braun Breakdown of academic impact, for papers by Dorothee M. Aeppli